Ladies and gentlemen, thank you for standing by, and welcome to the Q4 2020 Dentsply Sirona Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer session. [Operator Instructions] I would now like introduce your host today's conference call, Ms. Kari Dixon, you may begin.

Thank you, operator, and good morning, everyone. Welcome to our fourth quarter 2020 earnings conference call. I'd like to remind you that an earnings call press release and slide presentation related to the call are available on our website at www.dentsplysirona.com. Before we begin, please take a moment to read the forward-looking statements in our earnings press release. During today's call, we make certain predictive statements that reflect our current views about future performance and financial results. We base these statements and certain assumptions and expectations on future events that are subject to risks and uncertainties. Our most recent Form 10-K lists some of the most important risk factors that could cause actual results to differ from our predictions. In today's conference call, our remarks will be based on non-GAAP financial results. We believe that non-GAAP financial measures provide investors with useful supplemental information about financial performance of our business, enable the comparison of financial results between periods where certain items may vary independently of business performance and allow for greater transparency with respect to key metrics used by management in operating our business. Please refer to our press release for the reconciliation between GAAP and non-GAAP results. And with that, I'd like to now turn the call over to Don Casey, our Chief Executive Officer. Don?

Thank you, Kari, and thank all of you for joining us this morning. I hope you're all safe and well. It's hard to imagine that a year ago, on this call, we first started discussing the COVID-19 pandemic. And as we enter 2021, it is still a challenge that creates some level of uncertainty. But over the course of the year, there have been many lessons for Dentsply Sirona, and the experience has hopefully prepared us for the coming year and beyond. As we provide a final look at 2020, a few things really stand out. The first is the resilience of the dental market and how committed the dental community is to serving their patients. The second is how strong the underlying Dentsply Sirona business is. This is illustrated by the improvement in our results over the last two quarters. Learning new and different ways to do business has been another key lesson. Whether it was a virtual DS World, creating digital KOL forms or having our global R&D teams collaborate without physically being together, there is vital learning here that we will apply going forward. And finally, we have always talked about how our people are our most important asset. Well, 2020 certainly highlighted that. Every day, our team stayed focused on our customers and their patients despite dealing with professional and personal challenges that we all faced during the year. I want to thank them for their commitment and professionalism. Moving on. Today, we want to cover four things. The first is our fourth quarter results. After that, we will provide some guidance for 2021, and we will then provide some perspective on our priorities going forward, and we will finish with a discussion around our ESG plans. Moving now to Slide 6. We are pleased with our performance in the fourth quarter. Revenues were $1.1 billion, down 3.3% on an organic basis. This is a sequential improvement versus quarters two and three and reflects a gradual recovery in the dental market. In the fourth quarter, we remain disciplined around spending, and these cost-containment efforts helped deliver a solid margin performance. Operating margin reached 23.2%, up 320 basis points versus year ago, this results in an adjusted non-GAAP EPS of $0.87, up 19.2% versus the prior year. Other actions taken by the team helped generate healthy cash flow from operations of $263 million. To provide the details of our performance for the quarter, I will now turn the call over to Jorge.

Thank you, Don, and good morning. In the fourth quarter, we delivered strong results and exceeded our internal expectations in many categories. The steps we've taken to improve our business continue to generate positive financial outcomes despite the difficult environment created by the evolving global pandemic. Sequentially, during the fourth quarter, we delivered improvements on almost every key financial metric versus the third quarter. We capitalized on the gradual recovery in customer demand and commitment to cost discipline across the enterprise. While we remain cautious, our fourth quarter performance has given us good momentum going into fiscal 2021. Let's look at Q4 in more detail. Organic revenue decline of 3.3% versus last year was an improvement sequentially as compared to the 8.8% decline experienced in the third quarter. Consumables posted organic growth of 1.1% in the fourth quarter versus last year. We delivered strong Consumables growth in Europe and the U.S., offset by declines in other geographies. As expected, Technologies & Equipment organic sales declined 6.2% versus last year, primarily as a result of the difficult comparison for the CAD/CAM business relative to Q4 2019. Gross profit was $613 million or 56.7% of sales, a better-than-expected outcome, given this quarter's lower volume levels as compared to last year. The gross margin reduction was primarily due to the lower sales levels and negative absorption. It was partially offset by productivity and cost savings initiatives. SG&A decreased $58 million or 13.8% versus the prior year. SG&A as a percent of sales declined 430 basis points year-over-year. The reduction in SG&A reflects volume-related decreases and improvements in productivity and operational agility. Examples of volume-related expenses include travel, commissions, advertising and promotions. Also, we have been very prudent with nonessential and discretionary spending categories. Operating profit grew over 13% to $251 million versus last…

Thank you, Jorge, and we will move to Slide 14. To give additional perspective on 2021, it might be helpful to provide some detail around our strategy and operating priorities going forward. Moving to Slide 15. Over the past two years, the Company is focused on delivering against the restructuring outlined in late 2018. Despite the pandemic, Dentsply Sirona has made solid progress across most areas against the goals outlined in that restructuring. The plan was built around improving growth, driving margin and simplifying the organization. And while there is still work to do, our leadership team is committed to meeting those goals in the original time frame. As we get toward the conclusion of the restructuring, though, it now becomes important to lay out a strategy for how we will grow Dentsply Sirona in the future. As we have refined our growth strategy over the past few years, it is important to recognize that the dental market continues to evolve. Increasingly, our customers are looking for comprehensive solutions and improved workflows that deliver better patient outcomes and improve the financial health of their practices. Dentsply Sirona is uniquely suited to deliver this for our customers. Our company has an unmatched installed base of digital dental products, including both digital impressions and a complete range of x-ray imaging products. We have deep expertise in treatment planning and workflow management, and Dentsply Sirona has a full portfolio of essential consumer products that are critical components of many procedures. Putting all of this together, we will distinct -- putting all of this together will distinguish us going forward and provide sustainable differentiation. For 2021 and beyond, our operational priorities will remain consistent around delivering growth, improving margin and building a scaled, efficient company. Specific targets include organic growth of 4% to 5%…

Thank you, Don. Operator, we will now open for questions.

[Operator Instructions] Our first question comes from Nathan Rich with Goldman Sachs.

Hi, good morning. Thanks for the question. Don, maybe starting on the guidance, the revenue range is kind of back in line with 2019 levels. I know your business has a lot of moving pieces with kind of the M&A and the decisions to exit the traditional ortho and lab businesses. So I guess just at a high level, could you kind of talk about what your expectations are for the market relative to 2019? And then with -- when you look at kind of the composition of your portfolio, how would you kind of expect to perform relative to the market?

Yes. Thanks, Nate. It's interesting. What is the relevant comparison? Is it '19 or is it '20? Look, with the pandemic still lingering through this quarter and while we're optimistic about vaccines, we think that there's still going to be an impact that we'll see in our business in places like Latin America and others. So, we're kind of really looking at the guidance versus 2020 as kind of the relevant discussion. Look, in terms of what we expect over the course of the year, we see a gradual improvement. If you look at the ADA surveys and a lot of our survey work, you see, particularly like in the North American market, we think offices are operating 80%, 85%. There's been some compensation on the part of the dentists by looking at higher value procedures. So revenue has stayed up. We've actually seen, in some cases, dentists beginning to add fee -- fees for PPE to compensate for that. But our expectation based on our tracking studies that talk directly to patients, we see patient optimism starting to increase. And we think that will manifest itself kind of gradually over the course of the year. So, we think the exit rate for the total category in the back half of 2021 will be better than the front half. Just in terms of how does our portfolio stack up? Nate, look, I think other people are better qualified to answer how different people's portfolios are going to stack up. I would tell you this, as we kind of look at it, we start with our strategy, which we really think -- let's think about workflows and what workflows are important to us. Clear aligners is clearly an area that we've spent a lot of effort on, and we obviously feel…

Yes. I appreciate the color. If I could just ask a quick follow-up on the T&E segment, you said that it got better sequentially. I wonder if you could comment specifically on the digital equipment piece, how that performed relative to your expectations? And just how you feel about kind of the level of demand you're seeing in early 2021 as you think about your expectations for the full year?

Yes, Nate. And in both mine and Jorge's prepared remarks, we talked about, look, 2019 was a big comp coming off the fourth quarter. I mean, basically, you were in full -- in the critical North American market, you were in the middle of a Primescan upgrade, and you launched Primemill, and we had the One DS program. So, we knew that was going to be a pretty steep hill decline. Relative to our expectations, particularly without having a live DS World, the T&E segment actually performed pretty well. And as we look out to the first quarter, now let's remember the first quarter for us typically is slow. It's the smallest quarter over the course of the year, and obviously, T&E is a big part of that. But I would tell you the thing that has impressed us is that the -- if you really go back to the second quarter, I think in the North American, European markets, in particular, the dentists really were kind of, okay, what are -- when the pandemic kind of eases up, what are we going to do? And we've seen a lot of dentists that have really taken a step to say, hey, look, I want to get into implants. I want to do more clear aligners, which requires them to kind of up their diagnostic game, whether that's through like more 2D, 3D cone beam or whether that's getting what we think is a best-in-class scanner with Primescan. And we've seen underlying demand pretty good. I mean, if you actually -- one of the reasons we say that is if you look at how like North America performed comparative to Europe on some of like the CAD/CAM and the CEREC businesses, where you didn't have the impact of the DS World, you saw what we think was pretty solid demand for T&E. And we feel, as we come into this quarter, we're not getting ahead of ourselves, but we feel that underlying interest in our products has been pretty good. And with Primemill now coming, we feel that we've got a pretty winning but portfolio.

Next question comes from Glen Santangelo with Guggenheim Securities.

Good morning. Thanks for taking my question. Don, I just want to ask the market growth question maybe another way. You put up Consumables, organic Consumables just over 1%. And what we're having -- we're having a difficult time sort of reconciling that against these ADA surveys. And so would you sort of look at the numbers in the fourth quarter, now you have the luxury of sort of seeing January and February of this quarter before we hit these easier comparisons, is it fair to say that the market is now growing year-over-year? And I appreciate your comments. You said that there was a shift in promotional strategy. So can you just help us put maybe the market growth in context?

Yes. Glen, first, thanks for the question. Look, the Consumable market is kind of hard to parse apart because there's not a clean comparison as what is Consumables because you've got some people who report big PPE numbers and whatnot. When we talk about Consumables and us, it's really about like resto, lab and endo for us. And what we saw was in the fourth quarter, we had a good performance in the U.S. in particular, and we think that's been a result of a lot of the work that we had been doing around the promotional strategies. We're not quite as exposed as some of our other competitors may be areas in Asia Pacific that have returned from the pandemic a little bit faster. So in all, we were pretty happy with how Consumables performed. Now go below that a little bit. I mean, when -- and it was really funny. If you go back a year on this call because we report relatively late in the cycle, we were really the first people that were talking about an impact on coronavirus in the dental category. And one of the things we said is as dentists started heading into that kind of March uncertainty and April uncertainty, the easiest spigot to turn off was Consumables. Hey, we're not going to build inventory there. And we do think that while the ADA is saying 80, 80, 80-plus we do think that there was some benefits to not only the things we were doing, but there was some restocking as traffic begins to return to somewhat more normal levels. So -- and then, look, the promotional programs, we've said this, and I wish it was easy to just do that all in one quarter. But as we roll our promotional strategies…

I appreciate all that commentary. Maybe if I can just ask Jorge a quick follow-up question on the margins. Jorge, it's the second quarter in a row of margins coming in, I think, much better than everyone was expecting. And looking at your long-term guidance, it's almost hard for us to see how margins could go down so much from this point as fiscal '21. I know you talked about investing in innovation, new product launches. But on the other side of that, you're raising your cost savings targets and things like that. And so how should we think about that cadence in the margin? Because it feels like you have to take a pretty big dip from where you were in the second half of 2020 to kind of make sense of that guidance for fiscal '21?

Thanks, Glen. Good question. So a few things to keep in mind, the first I would say is you can't compare just Q4 with the average operating profit margin for the fiscal year because as you know, Q4 is typically the strongest from a sales perspective. That creates operating leverage, and it really helps the margin in that quarter. By the same token, you can't use, for example, Q1 as a good proxy for the average rate for the year because Q1 is the lowest quarter. So you have to think about how those numbers average out throughout the year. The mix in the quarter in Q4 was very good. We just talked about Consumables, and Consumables performed really well in the U.S. and in Europe. We're not only -- it was not only the U.S., but the U.S. and Europe had a good quarter from a Consumables perspective, and that is a good margin business. Then when you go down to expenses, on the expenses side, there are probably three main buckets, right? One is the cost takeout that we're doing structurally. And that is reflected in the guidance. It's reflected in the steady progression that we have delivered over the last several quarters and what we're projecting for '21. So there's going to be a significant amount of cost that is out on a permanent basis. There are two other buckets. One is spend that is volume-related. And as we increase volume, there is some variable cost that will be added to the equation, and we didn't have that in Q4 or Q3 because we are running at a lower-than-normal levels in volume, so that is important. There is discretionary spend and some other spend that as our volume grows, we probably will start spending some -- in…

Our next from Erin Wright with Crédit Suisse.

Great. Can you speak a little bit about the stepped-up R&D investments? Is it now a change from your previous targeted innovation approach? And were you holding back on product launches in this -- the pandemic? And should we anticipate a new product launches? Or should we anticipate that steady stream of innovation?

Yes. Erin, it's our objective to deliver a pretty steady stream of innovation. Look, in 2020, particularly in the second quarter, what we did was really kind of pull back and make sure we were focusing on kind of the big, really essential products. But as we've made all these changes really in kind of late '18 into '19, talk about portfolio, talking about moving to a procedure approach. We've got new leadership in R&D, and we're just taking a different approach. And the productivity we've seen, we thought we had a pretty good year in '19, where despite the pandemic, pretty happy with some pretty major products coming out in 2020. And what we know that we have in -- coming in 2021, we felt that the R&D organization is really efficient, and we're making further changes. I mean, we're super excited about creating a new innovation center that will focus on our Consumable and implants business. It's 60,000 square foot facility that we're going to be opening this year in Charlotte as kind of emblematic of how we're taking this cross-product procedure approach. So getting up to the $160 million that Jorge mentioned to me is just terrific spending because it's going to allow us to deliver innovation. Now, look, it's not going to be perfect every year. It's going to be on a glide path. But we think that kind of step-up in spending should enable us to deliver a stepped-up productivity from our organic efforts. So again, I'd love to say innovation is going to, hey, we're going to launch two in this quarter, two in that quarter, two in the next quarter. Some of that's going to be really timed off when the innovation comes. And just the last point, Erin, I'd add, as we -- I just mentioned in my prepared remarks, increasingly, we're really thinking about our digital footprint whether that's a huge installed base on the x-ray side or a very, very strong base on the CEREC side. How do we combine that in a way that allows dentists to really think about more complex workflows? And as a result, you start looking at all the software in the Company. And as you want that to start working together, that's an area that we're extremely excited about, our customers, some of the stuff we've shown our customers gets them -- gets their blood flowing, and that's another area that we're investing in. So I was telling our Board of Directors that, boy, it would be great if we're able to increase our R&D spending because that's the, in my opinion, the most efficient way for us generate organic growth going down in the future.

Okay. Great. And then can you speak about the clear aligner strategy now? And how you're balancing the DTC strategy with the practitioner-directed market? What is some of the initial feedback from your customers? Or any surprises with the Byte transaction since the close or incremental investments needed across the Byte?

We've had Byte for a couple of weeks, I guess six or seven weeks. The feedback from the dental community is almost exactly what we expected based on all the survey work we had done during the diligence process, which is dentists that are doing clear aligners think having another major entry in the clear aligner space is going to put more marketing emphasis and drive, in general, more patient traffic. So they're pretty positive. I think some general dentists that aren't necessarily doing clear aligner work today potentially look at that as competitive. I think a lot of that will dissipate when we bring the Byte program out to them. I mean basically, when we show them a concept where we're taking the hundreds of thousands, close to 1 million unique visitors that come into Byte, not all of them are going to be available for class one treatment. And we believe that gives us an opportunity to direct patient traffic at our network. So we believe that as we bring that story out and provide details, it's going to be pretty positive. And then the last discussion that we've seen is people ask us the question, well, if the dentists are negative about it, is there going to be any deleterious impact on purchase intent for Dentsply Sirona products? And a couple of things I'd point out. The first is we tend to be a house of brands as opposed to a branded house. So whether or not people know a Cavitron is a Dentsply Sirona product is actually one of the things I'm working to fix long term, but it's kind of hard to single out Dentsply Sirona products. And that's -- it's really funny. It's a blip that comes, and then it kind of goes away. So I would tell you that we're pretty happy with the response of the general dental population to Byte. That's question one. Question two, since we've had it, does it require any new investment or stuff like this? We have done a pretty thorough amount of diligence, and we kind of knew what it was going to take. Obviously, a start-up company, we're looking forward to the integration of like finance, QARA, some supply chain stuff. And that's really gone according to plan. We haven't seen any areas that require major investment. If anything, today, we're more excited about Byte than we were in January when we made the announcement.

Our next question comes from Kevin Caliendo with UBS.

I guess we want to talk a little bit about the cadence. We understand 1Q is always a little bit worse. You talked a little bit about demand in 4Q year-over-year. But I guess I'm asking as people start to expect to get vaccinations, sort of what you saw January, February, what you expect to see into March? I get it on the margin side and spend and everything else, but when we think broadly around dental and dental demand, are you still seeing that sort of year-over-year growth in January and into February?

Kevin, Jorge here. I don't want to get into January or February results at this point. It's too early. What I would tell you is that all the information that we have, the best information we have as of today, we have reflected in the outlook that we are providing. So as I indicated and Don indicated, we are seeing some stability in the dental industry. We are optimistic, cautiously optimistic about patient confidence. And all of those data points, the growth we've seen in certain areas, the trajectory of other parts of the business, all of that is factored into our outlook of '21 where we will see potentially organic growth in the 15% to 25% with second half stronger than the first half, Q1 typically lower than the other quarters. And I mean, that's everything we know we have, and that's what we have reflected in our guidance. I don't have really anything else to add to that.

No. That's fine. I appreciate that. I guess just one follow-up. You mentioned Primemill and some of the other products that you launched last year. And I'm guessing just given the way everything played out last year, there maybe are some orders or some potential. I don't know if there's still pent-up demand for any of your bigger ticket equipment items or not or how we should think about that as an impact to 2021. But any color around that would be great to understand as well.

It's interesting as we launched Axeos and Primemill, we were originally constrained from a production standpoint, then we kind of hit the pandemic. We used the pandemic to kind of gear up. We feel that we are in a really good place right now on Axeos and Primemill. One of the things that's interesting, Kevin, is with the urgency of an on-premise DS World like in Las Vegas, there's a certain urgency about purchasing right then and there. With kind of the virtual DS World, you don't see kind of that. Everything happens in the course of two weeks. So we're going to be interested to see kind of -- we have really good response to the virtual DS World. I mean, we had probably as many live prospects, real validated prospects as we did at the in-person event, but we're just -- we're going to be interested to see how long that tail is. So we don't anticipate there's a whole bunch of pent-up demand. We can make -- we're in a better position from a manufacturing standpoint today than we were a while ago, and we'll see. But again, underlying demand for digital dentistry products has been pretty good.

Our next question comes from Elizabeth Anderson with Evercore.

I was wondering if you could talk a little bit about your implant business and sort of any changes in sort of -- in terms of your plan to sort of accelerate more towards market growth and how new products are performing or the overall state of your branded products in that category?

Yes. It's interesting. I would say that we remain optimistic about the long-term opportunity that we have in the implant business. I think fourth quarter was one where I'd like to see us improve on our performance. I would tell you, the time that we've spent during the pandemic and looking at how we see the market evolving, we've improved our portfolio. I think we're optimistic about the things we're bringing to market over the course of this year. We added Datum, which we think is an important adjacency product. If you look at it, Elizabeth, we have between Atlantis and Datum, we think we have two really good adjacencies that allow us to be in a much better position today than we were even a year ago to go in and really make some noise around implants. We think our implant business will grow in 2021. So we feel good about that. And long term, we believe as digital dentistry and workflow management becomes increasingly important, we're very, very well positioned between the diagnostic expertise of our X-ray portfolio, which is critical around implants. We think our product portfolio will be rounding that out over the course of this year. And we think we've got great adjacencies that will allow us to be very, very competitive. And last, it's interesting. I -- we mentioned the sales force effectiveness program, and it's interesting. We don't really get a whole heck of a lot of questions on it, even though it represents about 1/3 of the people that work in Dentsply Sirona. And the thing that we've been doing in our sales force effectiveness program is really how do we go in and focus on, say, if it's a high-volume implant doc, how do we really make sure that we're bringing all of the resources of Dentsply Sirona to that doc. And we feel pretty good about the work we've done in the U.S., and we've now rolled that -- we're in the process of rolling that out to 10 more countries. So again, getting our commercial sales force effectiveness program rolled out, we think, is going to be helpful. So long term, we think there's nothing but upside on our implant business.

That makes a lot of sense. And can you also talk about sort of more broadly maybe your new product rollout as we think about the course of 2021, how you think about it in light of the both the reopening and then obviously, some of the investments you're making this year, which I assume will translate into some impact this year, but probably more down as 2022, maybe 2023 type of event. Can you talk about sort of that piece at all and sort of how you view it longer term?

Sure. Look, in the -- we're truly a global company, and I'm reminded of that every day. So when we say we launched Primemill, okay, we launched in North America and some selected countries in Europe, and we're now in the process of rolling that out. Axeos is the same thing. Axeos was a North American launch. So are we bringing something new to the market? Well, we're bringing something new to various markets around the world. So as we think about it right now, stuff like Sure -- the things I called out, Surefil one, Axeos, Palodent 360, we've got a pretty good rhythm of taking products that we may have launched in one place and rolling that out. And we think that's going to give us some pretty good momentum through the beginning of the year. And then in the back half of the year, a lot of the stuff that we are working on in late '19 and through 2020 will come to fruition. And then the step-up in R&D investment, you almost have to think of that in a bifurcated way. The first is software is increasingly important to us, and that comes out a little bit faster. And then products that are 510(k) or longer-term clinical or have longer-term clinical requirements, that's obviously going to come out a little bit later. But I think one of the accomplishments that I'm proudest of the team that they made over the course of the last year and plus, I mean, I really feel like our R&D engine is where we need it to be. And I think it's focused on a broader idea of like how do we win in a procedure, starting from a diagnosis going to a treatment plan and delivering great Consumables that are all synced up is the right way to go. So long term, we're optimistic that you'll see an acceleration of what we're able to do from an organic perspective.

Next question comes from Steven Valiquette with Barclays.

Great. A couple of questions here. I guess, first, all the color on the 2021 guidance has been helpful so far. One area where there was less color was just around the gross margin expectations for '21. Curious to hear more about the puts and takes that can cause variability there, as we think about the gross margins exiting 2020 at just under 57%, is that a good run rate to use for '21 overall? And then just quickly on the R&D, the $160 million expense in '21, can you just tell us roughly what the R&D expense was for 2020, just to give us a sense for the comparison?

Let me start with the second question. The number for R&D in 2020 was about $115 million total. So we're going from $115 million to $160 million in '21. And going forward, we are going to be very, very transparent about our R&D spend, and you'll see -- you guys will see that on the face of the financials. With respect to gross margin, gross margin fluctuates from quarter-to-quarter, similar to operating profit margin. Our expectation is that we will steadily increase gross margin a little bit as well. Some of the cost savings as part of the $250 million target are coming from gross margin improvements. We continue to do a lot of work from a manufacturing facility optimization. There is indirect procurement initiatives that we have. And there is a number of other things within COGS that should help our gross margin. I don't expect to see a significant change going into 2021, but we should have some small improvement there.

Our next question comes from Tycho Peterson with JPMorgan.

Jorge, I just want to stick with the guidance for a minute. I'm just wondering if you can break out what you're expecting for FX, M&A and divestiture headwinds. And then you're not giving segment level guidance. I'm just curious how we should think about T&E versus Consumable growth this year?

Yes. Thanks, Tycho. FX, for us, FX is mostly impacted by the euro. And so we -- I can give you roughly the assumption we have for the euro-dollar exchange rate is about 1.22. That's what essentially what we're using for modeling purposes in the budget. With respect to M&A, we are not modeling anything included in the outlook we have provided. Similarly, there's no divestitures either. So there's nothing contemplated in those areas in the outlook that we have provided.

So just could you clarify what the revenue contribution you're expecting from Datum is then because you've already talked about Byte, but what are you expecting? And I know it's only $95 million deal, but what does that add?

It's really not material to the revenues of the Company. We have not disclosed the total number, but it's not really big at the beginning, Tycho.

Okay. And then you raised the long-term outlook to 4% to 5%. Obviously, that captures the 300 basis points you're going to get from clear aligners this year. But you've also talked about 20% to 25% growth for the clear aligner segment. So I'm just curious, that 4% to 5%, I guess, looks like it could be conservative in the long run. Is that a fair assessment?

Well, the 4% to 5%, essentially, what we did was we had talked about 2% to 3% or 3% to 4% long-term growth rate from a top line perspective. With the acquisition of Byte and the acceleration of our clear aligner business, we believe that those two businesses should add about 1.5%, maybe a little bit more of top line growth. And we'll do everything we can to improve that, but that, we believe, is doable, and that's what we are modeling in the outlook that we have provided.

Okay. And then last one, I just want to go back to Datum for a minute. I know it's a small deal, not a real revenue contributor. But as we think about Astra Tech and Ankylos and some of these products, can you just talk about how you see synergies there, Don, for the implant business?

Yes, sure. Tycho, it's interesting as patients have looked at implants, I think the biggest trends they've said they want faster results, which is resulting in a lot of kind of more immediate load implant systems. And when you do immediate load, one of the things that gives dentists a fair amount of confidence is putting in some kind of a bone growth factor around the immediate load screw to kind of accelerate the healing process. So we look at Datum as it's a great technology. I mean, we believe it's clinically superior to anything else in the marketplace. Being able to go in with a relevant kind of piece of news about, hey, as you think about immediate load systems, one of the best ways to accelerate healing is to use OSSIX. So that's kind of how we're thinking about it. Now obviously, as we need to update our portfolio, we've been -- we've tended over the last eight years to have been much more of a parallel wall implant system company. And we have, we think, a clear opportunity to begin to expand our portfolio to allow us to compete more aggressively in the faster-growing immediate load space.

Our next question comes from Jeff Johnson with Baird.

I'll try to be brief here just given the time, but going back just to R&D real quickly. Jorge, historically, we thought of Dentsply kind of being about a 3% of revenue R&D spender. Obviously, with the guidance this year, it's going to be up around 4%. Is that about the right number kind of R&D after 2021 kind of grow in line with revenue? Just thinking longer term, kind of holding it closer to that 4% or is there upward bias even on that number then going forward?

Thanks, Jeff. Now this is a topic that we have spent a lot of time on, and we believe that around 4% ratio as a percent of sales is a good number for us at least for the foreseeable future. Dollars-wise is a significant improvement. As I indicated earlier, in 2020, we spent about $115 million. We're going to $160 million. That is a substantial amount of incremental dollars. We are working very closely with the R&D team, making sure that we have the right metrics and that we really track the return on those investments. And we are comfortable with the 4%. We think that 4% or so is going to be essential, critical for the top line growth, and we're going to rely significantly on organic growth to deliver that top line.

Yes. Understood. And then, Don, just the bigger picture for you. You guys have been talking about this 3% to 4% organic and double-digit EPS. Obviously, with Byte, you take that organic up to 4% to 5% kind of on the long-term guide. 2020 and even 2021, there's some funkiness in those years. So you can't really apply those targets to that. Is '22 that first year, understanding you just put out '21 guidance, but not -- so not to ignore that. But is '22 that first year where we can think about those long-term targets coming into play of 4% to 5% and double digits and kind of growing our models beyond that in future years then?

Yes, Jeff, we give you '21 and you ask for '22. Look, that's probably a fair assessment, Jeff. Look, as one of the challenges, and I give Jorge and his team a whole lot of credit is how do you look at 2021 in context of 2020? And again, it's not clean to go back to '19. But look, we think we have a formula how to grow the business, which is how do you see Consumables growing? How do you see technology and equipment growing? Combined is we bring stuff like Byte on. And when we -- you see investments in R&D and things like that, we'd like to see our implant business growing as well. So yes, we think 5 -- 4% to 5% plus is where we want to be. And as we think of '22 and beyond, absolutely. We -- again, if you really kind of look at the last two years, I mean, it was, okay. In late '18, we got to get the Company structured correctly. We think we've done that work. We think we've got a good recipe for growth. We've added some organic and inorganic acceleration to it, and that's why we say we think we should be four to five plus.

Our next question comes from Jon Block with Stifel.

This is Trevor on for John. So just on the 15% to 25% range that you gave for guidance, are there any specific variables to Dentsply Sirona that you can call out that could take you to the higher low end of this range? Or is it really driven by the market and macro factors that you called out?

Yes. Thanks for the question. Obviously, there's a number of factors that play into this range. One thing that we indicated in our prepared remarks is the overall trajectory of the market as a function of what happens with the COVID dynamic and vaccine rollouts. That plays an important role. Then more specifically related to the Company, there is the performance of our new launches, and Don talked about how we are beginning to roll out Primemill, Axeos and other products more globally. That should also influence where we end in that part of the range. And then the growth trajectory of our clear aligner business is an important factor into our outlook for '21. So there's a number of things, but I think those are the major ones.

Our next question comes from Michael Cherny with Bank of America.

This is Allen in for Mike. Don, you mentioned margin opportunity around procurement and logistics. Can you expand a little on that? And is that something that can be done just internally? Or are you looking at partnerships or potentially M&A for that?

No, that's really internal stuff. I mean, look, we used to run a pretty disaggregated supply chain. And Dan Key and his team have done a great job of creating a unified group. Obviously, that's taken a little bit of time. We really started that in earnest in 2019. And as we've gotten scale, we're now able to look at total Dentsply Sirona from a procurement basis as well as a logistic basis. And as we think about things, we've been able to consolidate distribution points and a few other things that have given us some leverage and we expect to continue giving us leverage in the future.

Okay, great. Well, that concludes today's session. Thank you, everybody, for joining us today on our fourth quarter 2020 earnings conference call. We look forward to having follow-up discussions with many of you later today.

Ladies and gentlemen, this does conclude today's presentation. You may now disconnect, and have a wonderful day.